Healthcare

UAE investment drives biopharma transformation through AI and precision medicine

A World Health Expo-Frost & Sullivan report says UAE investment in genomics, AI, and advanced manufacturing is accelerating precision medicine and AI-enabled drug discovery. It cites the Emirati Genome Program and Insilico Medicine’s Abu Dhabi operations.

A World Health Expo and Frost & Sullivan report says the UAE is investing in genomics, artificial intelligence, and advanced manufacturing to expand biopharmaceutical capabilities. The report projects Middle East precision medicine growth of 10 to 12% annually over the next five to seven years.

The Emirati Genome Program is targeting one million genetic samples, while the UAE Reference Genome study is analyzing more than 50,000 samples. These initiatives are intended to support disease prevention, precision treatment, and healthcare research.

The article also highlights Abu Dhabi-based AI drug-discovery activity. Insilico Medicine’s Abu Dhabi center reportedly nominated the UAE’s first fully AI-discovered preclinical candidates for oncology and non-opioid pain in 2025.

The development matters because it links national genomics infrastructure with AI-assisted pharmaceutical research and precision medicine. However, the article is a press release and its market projections are attributed to Frost & Sullivan rather than independently audited data.

Original source: Pharmaphorum

Related RAQI solutions

In-depth analysis on RAQI Insight

Work with RAQI